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Abstract: Changes in sphingolipid metabolism have been suggested to contribute to the
pathophysiology of major depression. In this study, we investigated the activity of acid and neutral
sphingomyelinases (ASM, NSM) and ceramidases (AC, NC), respectively, in twelve brain regions of
female rats selectively bred for high (HAB) versus low (LAB) anxiety-like behavior. Concomitant
with their highly anxious and depressive-like phenotype, HAB rats showed increased activity of
ASM and NSM as well as of AC and NC in multiple brain regions associated with anxiety- and
depressive-like behavior, including the lateral septum, hypothalamus, ventral hippocampus, ventral
and dorsal mesencephalon. Strong correlations between anxiety-like behavior and ASM activity were
found in female HAB rats in the amygdala, ventral hippocampus and dorsal mesencephalon, whereas
NSM activity correlated with anxiety levels in the dorsal mesencephalon. These results provide
novel information about the sphingolipid metabolism, especially about the sphingomyelinases and
ceramidases, in major depression and comorbid anxiety.
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1. Introduction
Major depressive disorder (MDD) is a severe and chronic mood disorder, with a lifetime prevalence
of approximately 11% in men and 18% in women [1]. MDD is highly comorbid with other psychiatric
disorders, including generalized anxiety, social anxiety and alcohol use disorders, and is associated
with increased suicidality [2]. The major symptoms of MDD are a depressed mood and loss of
interest, anhedonia, feelings of worthlessness, weight loss and insomnia. Despite its severity and
high prevalence, the pathogenesis of MDD is yet unclear. One of the mechanisms involved in the
pathogenesis of MDD seems to relate to an altered metabolism of sphingolipids such as sphingomyelin
and ceramide [3]. The enzyme sphingomyelinase catalyzes the hydrolysis of sphingomyelin to
ceramide and phosphorylcholine [4]. Depending on the pH optimum of the enzyme, several isoforms
are known, including acid sphingomyelinase (ASM), neutral sphingomyelinase (NSM) and alkaline
sphingomyelinase [5]. As expected from their pH optimum, these enzymes are differentially localized
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throughout the body. As such, ASM is ubiquitously distributed in all tissues [6] with a lysosomal
form but is also constitutively secreted [7]. NSM is predominantly localized in the central nervous
system [8,9], and alkaline sphingomyelinase is active in the digestive system but not in the central
nervous system [10]. Similar to sphingomyelinases, ceramidases differ in their pH optimum for the
breakdown of ceramide to sphingosine and fatty acid. The acid ceramidase (AC) and neutral ceramidase
(NC) show much higher activities in the brain compared to peripheral tissues [9]. An alkaline isoform
was detected in the human cerebellum [11].
Several clinical studies reported an altered sphingomyelin and ceramide metabolism in MDD.
As such, ASM activity was increased in peripheral blood mononuclear cells of patients experiencing a
major depressive episode [12]. Moreover, secretory ASM activity was related to depression severity
and predicted the improvement of depressive symptoms during therapy [13]. Such alterations in ASM
activity might involve changes in alternative splicing of the gene coding for ASM, which differed
between MDD patients and healthy controls [14,15]. Similarly, several plasma ceramide species were
increased in patients experiencing a major depressive episode during the past two years compared with
healthy controls and patients experiencing a major depressive episode for more than two years [16].
Higher plasma ceramide Cer16:0, Cer18:0, Cer20:0, Cer22:0, Cer24:0 and Cer24:1 levels were also
observed in patients with MDD and bipolar disorder [17], and higher plasma levels of ceramide Cer16:0
and Cer18:0 were associated with higher severity of depression symptoms in patients with coronary
artery disease [18]. In contrast, plasma sphingomyelin SM26:1 [19], SM39:1 and SM39:2 [20] levels
were decreased in MDD patients, and the SM23:1/SM16:0 ratio was negatively correlated with the
severity of depression symptoms in a Dutch family-based lipidomics study [21].
Similarly increased ASM activity resulting in decreased sphingomyelin and increased ceramide
concentrations was described in rodent models of MDD. For example, exposure to chronic unpredictable
stress, which was shown to induce a depressive-like and anxious phenotype [22,23], increased the
levels of several ceramide species in the hippocampus and frontal cortex but not in the amygdala
and cerebellum in mice [24]. In contrast, sphingomyelin concentration was reduced by chronic
unpredictable stress [24], suggesting an altered sphingolipid metabolism. Chronic administration
of corticosterone, another model known to induce a depressive-like and anxious phenotype [25–27],
also increased ceramide concentrations in the dorsal and ventral hippocampus [28]. The direct
involvement of ceramide in the pathogenesis of depression was demonstrated in naïve mice,
which developed a depressive-like but not an anxious phenotype after infusion of Cer16:0 ceramide
into the dorsal hippocampus, whereas infusion of Cer8:0 or Cer20:0 ceramide exhibited no effect [29,30].
Interestingly, infusion of Cer16:0 ceramide into the basolateral amygdala induced an anxious but not a
depressive-like phenotype in mice [30], demonstrating the complex species- and brain-region-specific
modulation of emotional behavior by ceramide. Significant associations between ASM activity and
depressive-like behavior were also described in transgenic mice overexpressing ASM throughout
the body (ASMtg). These ASMtg mice showed an increased serum and hippocampal ASM activity
and an increased hippocampal ceramide concentration that was associated with a depressive-like
and anxious phenotype [29,31,32]. Interestingly, female but not male ASMtg mice also showed a
social anxious phenotype [31], suggesting an association between increased ASM activity and deficits
in social behavior in females. Sex-specific and brain-regional effects of ASM activity on emotional
behavior were also demonstrated in conditional transgenic mice in which the overexpression of ASM
was restricted to the forebrain (ASMtgfb). In these ASMtgfb mice, males showed higher ASM activity
in the frontal cortex, hippocampus, lateral septum and amygdala that resulted in a depressive-like
phenotype, whereas females showed a higher ASM activity in the hypothalamus and a social anxious
phenotype but not a depressive-like phenotype [33]. Despite this improved understanding of the effects
of ASM and ceramide on MDD, little is known about the involvement of other sphingomyelinases and
ceramidases in the pathophysiology of MDD or anxiety [34].
In this study, we characterized the brain activity of ASM and NSM as well as of AC and NC
in an animal model of innate hyper-anxiety and MDD, namely, in Wistar rats selectively bred for
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extremely high (HAB) versus low (LAB) anxiety-like behavior, based on their performance on the
elevated plus maze (EPM). This model is highly relevant for studying the sphingolipid metabolizing
enzymes, as HAB rats show an anxious and depressive-like phenotype similar to ASMtg and ASMtgfb
mice but not a social anxious phenotype [35,36]. On the other hand, LAB rats show a low level of
anxiety and depressive-like behavior when compared with HAB rats and unselected Wistar rats [37].
Given that MDD is more prevalent in women [38] and the social anxious phenotype was observed
only in female ASMtg [31] and ASMtgfb mice [33], experiments were performed in female HAB and
LAB rats.
2. Materials and Methods
2.1. Animals
Female HAB and LAB rats were bred at the University of Regensburg. Rats were kept in colonies
of 4 rats per cage under standard laboratory conditions (12:12 light-dark cycle, lights on at 06:00,
22 ◦C, 60% humidity, food and water ad libitum). Experiments were performed during the light
phase in accordance to the Guide for the Care and Use of Laboratory Animals of the Government of
Unterfranken (project identification code: 55.2-2532-2-384, approved on 06.04.2017) and the Guidelines
of the NIH.
2.2. Experimental Design
At 9 weeks of age, the anxiety-like behavior of the rats was tested in the EPM. At 11 weeks of
age, the naturally occurring social preference of the rats, as an indicator of social anxiety-like behavior,
was tested in the social preference test (SPT). One week later, the depressive-like behavior of the rats
was tested in the novelty-suppressed feeding paradigm (NSF). Twenty-four hours later, the rats were
rapidly decapitated under CO2 anesthesia and their brains were removed, snap frozen and stored at
−80 ◦C until further analysis. Twelve brain regions (i.e., the frontal cortex, dorsal and ventral striatum,
lateral septum, amygdala, dorsal and ventral hippocampus, thalamus, hypothalamus, dorsal and
ventral mesencephalon and cerebellum) were dissected out of coronal brain slices based on previous
studies [30,39]. The activities of ASM and NSM as well as of AC and NC were analyzed from one
hemisphere, counterbalanced between rats.
Experiments were performed in two batches of rats. In the first batch (n = 14 HAB rats and n = 15
LAB rats), all behavioral tests were performed as described above. In the second batch (n = 8 HAB rats
and n = 8 LAB rats), the anxiety-like behavior was tested on the EPM at 9 weeks of age, and brains
were collected at a comparable time point to the first batch. The activities of ASM, NSM, AC and NC
were analyzed from both batches combined.
2.3. Elevated Plus-Maze Test (EPM)
The anxiety-like behavior of the rats was tested in the EPM as previously described [36]. The EPM
consisted of two closed arms (50 × 10 × 40 cm; 10 lx) and two open arms (50 × 10 cm; 40 lx) connected
through a central neutral zone (10 × 10 cm) elevated 70 cm from the floor. Rats were placed into the
neutral zone facing one closed arm, and the 5-min test was recorded. A decreased percentage of time
spent on the open arms indicated increased anxiety-like behavior.
2.4. Social Preference Test (SPT)
The naturally occurring social preference of the rats, as an indicator of social anxiety-like behavior,
and the preference for social novelty of the rats, as an indicator of social recognition, were tested in the
SPT as previously described [31,40]. Rats were placed in a novel arena (80 × 40 × 40 cm) and allowed
to habituate for 30 s. Two identical wire-mesh cages (20 × 9 × 9 cm) were simultaneously placed at
opposite side-walls of the arena for 5 min. One cage remained empty, and one cage contained an
age-matched unfamiliar female rat (same rat). The initial position of the same rat varied between
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experimental rats to prevent possible place preference. After 5 min, the empty cage was exchanged by
an identical cage containing a novel female rat for an additional 5 min. Experiments were recorded,
and the time spent investigating (sniffing) the empty cage, the same and the novel rat was analyzed
using JWatcher (Version 1.0, Macquarie University and UCLA). A higher investigation time directed
toward the same rat versus the empty cage during the first 5 min indicated social preference and thus
a lack of social anxiety. A higher investigation time directed toward the novel versus the same rat
during the second 5 min indicated social recognition and preference for social novelty.
2.5. Novelty-Suppressed Feeding Paradigm (NSF)
The depressive-like behavior of rats was tested in the NSF as previously described [30,31].
Rats were food-deprived for 24 h prior to testing with unlimited water access. Rats were placed in
a novel arena (80 × 80 × 40 cm) with the head facing one of the corners. Immediately afterwards,
a single food pellet (ssniff Spezialdiäten GmbH, Soest, Germany) was placed in the center of the arena.
The latency to feed, defined as biting the food pellet for longer than 3 s, was manually analyzed.
An increased feeding latency indicated depressive-like behavior. The test lasted maximally 20 min.
HAB rats that did not feed within these 20 min (56% of rats) were not removed from the study but
were allocated 1200 s as their feeding latency value.
2.6. Measurement of Sphingomyelinase and Ceramidase Activities
The activity of sphingolipid metabolizing enzymes was determined using the fluorescent substrate
BODIPY-FL-C12-SM (N-(4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-indacene-3-dodecanoyl)
sphingosylphosphocholine, D-7711, Thermo Fisher Scientific, Waltham, MA, USA) for
sphingomyelinases and NBD-C12-ceramide (Cayman, obtained from Biomol, Hamburg, Germany)
for ceramidases, with four replicates for each sample based on a previously established method [41].
Tissues were homogenized in lysis reagent (250 mM sucrose, 1 mM EDTA, 0.2% Triton X-100, 1× Roche
protease inhibitor cocktail; approximately 200 µL/10 mg tissue) using a Tissue Lyser LT bead mill
(Qiagen) with steal beads followed by freezing at −80 ◦C to enhance lysis. Supernatants obtained
after thawing, ultrasound treatment (water bath for 60 s) and centrifugation at 16,000× g at 4 ◦C for
10 min were diluted 1:4 in lysis reagent and used for activity assays and for protein determination
(Bradford/Coomassie kit, Thermo Fisher Scientific, Waltham, MA, USA). A standard enzyme reaction
in a 96-well polystyrene plate contained 58 pmol sphingomyelin or 50 pmol ceramide as a substrate
in a total volume of 50 µL of reaction buffer of the following composition: 200 mM sodium acetate
buffer (pH 5.0), 500 mM NaCl, 0.2% IGEPAL® CA-630 (NP 40) detergent for ASM, 200 mM HEPES
buffer (pH 7.0), 200 mM MgCl2, 0.05% IGEPAL® CA-630 (NP 40) for NSM; 200 mM sodium acetate
buffer (pH 4.5), 100 mM NaCl, 0.03% IGEPAL® CA-630 (NP 40) for AC and 200 mM HEPES (pH 7.0),
100 mM NaCl, 0.03% IGEPAL® CA-630 (NP 40) for NC. The reaction was initiated by the addition
of 2 µL of tissue lysate corresponding to 0.5–1 µg protein. After incubation at 37 ◦C for 1–18 h,
depending on enzymatic activity, reactions were stopped by freezing at −20 ◦C and stored until further
processing. To separate product and uncleaved substrate, 1.5 µL of each reaction were directly spotted
on silica gel 60 thin layer chromatography plates (ALUGRAM SIL G, 818232, Macherey–Nagel, Düren,
Germany) and separated using ethyl acetate with 1% (v/v) acetic acid as a solvent. Signals were
detected on a Typhoon Trio scanner (488 nm excitation, 520 nm emission, 325–385 V, 100 µm resolution,
GE Healthcare Life Sciences, Buckinghamshire, UK) and quantified with the ImageQuant software
(GE Healthcare Life Sciences, Buckinghamshire, UK). Enzymatic activities were calculated as the
hydrolysis rate of sphingomyelin or ceramide (pmol), respectively, per time (h) and per protein (µg).
2.7. Statistical Analysis
For statistical analysis, SPSS (Version 21, SPSS Inc., Chicago, IL, USA) was used. Data were
analyzed using the Student t-test and two-way ANOVA for repeated measures, followed by a
Bonferroni post-hoc analysis whenever appropriate. Spearman correlations were calculated to evaluate
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associations between behavior and enzyme activities within groups. Statistical significance was set at
p < 0.05. For each parameter, outliers deviating more than two standard deviations from the mean
were excluded from analysis. Graphs were prepared using GraphPad Prism 7.00 (GraphPad Software
Inc., San Diego, CA, USA).
3. Results
3.1. Behavioral Phenotype of HAB and LAB Females
The expected highly anxious and depressive-like phenotype of HAB females compared with
LAB females was visible in both the EPM (T(40) = −40.02; p < 0.001; Figure 1a) and NSF (T(26) = 5.63;
p < 0.001; Figure 1b), respectively. In the SPT, all rats displayed normal social preference and a lack of
social anxiety (stimulus effect F(1,52) = 246.64; p< 0.001; group× stimulus effect F(1,52) = 1.90; p = 0.174;
Figure 1c). Furthermore, all rats displayed normal social recognition and preference for social novelty
(stimulus effect F(1,52) = 44.38; p < 0.001; group × stimulus effect F(1,52) = 0.43; p = 0.514; Figure 1d).
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Figure 1. The behavioral phenotype of female HAB and LAB rats. (a) Percentage of time spent on
the open arms of the elevated plus-maze, as an indicator of anxiety-like behavior; (b) Feeding latency
shown in the novelty-suppressed feeding paradigm, as an indicator of depressive-like behavior; (c,d)
Percentage of investigation time of the empty cage, the same and the novel female rat shown during
the first (c) and second (d) 5 min of the social preference test, as indicators of social anxiety-like
behavior and social recognition, respectively. Female HAB rats showed an anxious and depressive-like
phenotype compared with LAB rats but unaltered social anxiety and social recognition. Data represent
individual data points with means ± SEM. * p < 0.05.
3.2. Enzyme Activities in Selected Brain Regions of HAB and LAB Females
HAB females showed an increased ASM activity in the lateral septum (+40%, T(40) = 2.52;
p = 0.016), hypothalamus (+15%, T(42) = 3.40; p = 0.001), ventral hippoca pus (+10%, T(41) = 2.31;
p = 0.026) and ventral mesencephalon (+11%, T(41) = 2.42; p = 0.020) compared with LAB females,
whereas no differences in ASM activity were found in the frontal cortex, amygdala, dorsal hippoca pus,
dorsal and ventral striatum, dorsal mesencephalon, thalamus and cerebellum (Figure 2a). HAB females
showed an increased NSM activity in the ventral mes ncephalon (+10%, T(39) = 2.08; p = 0.044) but no
significant differences in the othe brain regions (Figure 2b). HAB females also showed an increased
AC activity in the d rsal (+24%, T(43) = 3.69; p < 0.001) and v ntral (+20%, T(42) = 2.98; p = 0.005)
triatum, hypothalamus (+25%, T(41) = 3.50; p = 0.001), thalamus (+27%, T(43) = 2.18; p = 0.035) and
ventral mesencephalon (+21%, T(41) = 2.10; p = 0.042) (Figure 2c) and an increased NC activity in
the hypothalamus (+42%, T(41) = 2.84; p = 0.007) and dorsal mesencephalon (+13%, T(41) = 2.37;
p = 0.022) compared with LAB females (Figure 2d). The only enzymatic activity t t was decreased in
HAB females compared with LAB femal s wa the NC activity in the amygdala (−62%, T(42) = −2.47;
p = 0.019) (Figure 2d).
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Figure 2. The activity of sphingolipid metabolizing enzymes in brains of female HAB and LAB rats.
The activity of acid and neutral sphingomyelinases (ASM in (a), NSM in (b)) as well as of acid and
neutral ceramidases (AC in (c), NC in (d)) was analyzed in the frontal cortex (FC), dorsal striatum (DS),
lateral septum (LS), ventral striatum (VS), amygdala (AM), dorsal hippocampus (DH), thalamus (TH),
hypothalamus (HY), ventral hippocampus (VH), dorsal mesencephalon (DM), ventral mesencephalon
(VM) and cerebellum (CE). HAB rats showed a significant increase in the activity of these enzymes
compared with LAB rats. Data represent individual data points with means ± SEM. * p < 0.05.
3.3. Correlations between Behavior and Enzyme Activities in HAB and LAB Females
In addition to the observed group differences, enzyme activities were lso related to depression-
and anxiety-like behavior within the groups. The anxiety-like behavior expressed as percentage time
spent on the open arms of the EPM negatively correlated with ASM activity in the amygdala (r = −0.48;
p = 0.031), ventral hippocampus (r = −0.57; p = 0.008) and dorsal mesencephalon (r = −0.60; p = 0.006)
and with NSM activity in the dorsal mesencephalon (r = −0.64; p = 0.002) in HAB females but with
none of the parameters in LAB females.
Depressive-like behavior expressed as latency to feed after a 24-h food deprivation period in the
NSF negatively correlated with AC activity in the frontal cortex in LAB females (r = −0.62; p = 0.015)
but with one of the parameters in HAB females. This lower number of correlations between enzyme
activities and depressive- ve sus anxiety-like b havior might be due to the lowe number of rats in
which depressive-like behavior was assessed (n = 29 v rsus n = 45).
4. Discussion
Our study describes for the first time the activity of sphingomyelinases and ceramidases in the
brain of rats with high and low levels of innate anxie - and depressive-like behavior. Concomi ant
with their highly anxious and depressive-like phenotype, HAB at showed increased a tivi y of
ASM and NSM as well as of AC and NC in multiple brain regions associated with anxiety- and
depressive-like behavior, including the lateral septum, hypothalamus, ventral hippocampus and
ventral and dorsal mesencephalon.
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These findings extend previous reports of increased brain ASM activity in transgenic models of
MDD, namely, in ASMtg [29] and ASMtgfb mice [33]. As such, increased ASM activity was previously
described in the dorsal and ventral hippocampus in ASMtg mice overexpressing ASM in the whole
body [29] (no other brain regions were tested in this study), whereas in ASMtgfb mice overexpressing
ASM only in the forebrain [33], ASM activity was increased in multiple brain regions. As such,
both male and female ASMtgfb mice showed increased ASM activity in the dorsal striatum, dorsal and
ventral hippocampus and amygdala compared with wild-type controls. Furthermore, male ASMtgfb
mice showed higher ASM activity compared with female ASMtgfb mice in all these regions except
in the dorsal striatum where the ASM activity was similarly high in both male and female ASMtgfb
mice. In the hypothalamus, the activity of ASM was increased in female but not in male ASMtgfb mice,
whereas in the frontal cortex, lateral septum and ventral mesencephalon, the ASM activity was increased
in male but not in female ASMtgfb mice. Despite this increased ASM activity, female ASMtgfb mice did
not show an anxious and depressive-like phenotype [33]. In contrast, the behavior of the male ASMtgfb
mice and female HAB rats clearly changed, displaying a significant anxious and depressive-like
phenotype in the EPM and NSF, respectively. By directly comparing these two animal models of MDD
with similar behavioral deficits, an important role of the lateral septum and ventral mesencephalon in
anxiety- and depressive-like behavior might be suggested, as female HAB rats and male ASMtgfb mice
but not female ASMtgfb mice showed an increased ASM activity within these brain areas. Given that
the lateral septum plays a critical role in regulating processes related to mood and motivation [42,43]
and is neuroanatomically connected with several brain regions known to regulate emotional behavior
(e.g., the hippocampus, amygdala, hypothalamus and the mesolimbic system [44]), it is feasible that
ASM within the lateral septum and ventral mesencephalon regulates anxiety- and depressive-like
behavior. The ASM within the amygdala, ventral hippocampus and dorsal mesencephalon might
also regulate anxiety- and depressive-like behavior given that a negative correlation between anxiety
levels and ASM activity was found in these brain regions in female HAB rats, i.e., rats that spent less
time on the open arms of the EPM and were thereby more anxious also showed higher levels of ASM
activity in the amygdala, ventral hippocampus and dorsal mesencephalon. However, the increased
ASM activity within the amygdala and ventral hippocampus in female ASMtgfb mice did not result in
an anxious and depressive-like phenotype [33], suggesting a differential contribution of the amygdalar
and ventral hippocampal ASM to anxiety- and depressive-like behavior in these two animal models of
MDD. An indirect involvement of amygdalar ASM in anxiety-like behavior has been already suggested
in a previous study that showed that infusion of Cer16:0 ceramide into the basolateral amygdala
induced an anxious phenotype in mice [30]. As ceramide is generated by the activity of ASM, a higher
ASM activity might be expected to increase ceramide levels. It is also possible that a very high level
of ASM activity within the amygdala and ventral hippocampus, as seen in male but not in female
ASMtgfb mice [33], might be necessary to elicit changes in anxiety- and depressive-like behavior in this
transgenic mouse model.
We also aimed to identify the brain region/s contributing to ASM effects on social anxiety by
comparing the alterations in ASM activity between female ASMtgfb mice with social anxiety and female
HAB rats without social anxiety. However, for now we cannot suggest which brain region mediates
these effects. Based on the study performed in ASMtgfb mice, the hypothalamus was a promising brain
region given that the ASM activity was increased in female but not in male ASMtgfb mice and that
only female ASMtgfb mice showed a social anxious phenotype [33]. Although the hypothalamus is
highly relevant for several types of social behavior, including social anxiety [45], it is unlikely that the
increased ASM activity within the hypothalamus contributes to social anxiety in general, as female
HAB rats were not socially anxious despite the increased ASM activity in the hypothalamus. In female
HAB rats, the increased ASM activity in the hypothalamus seems to relate more to their depressive-like
behavior, given that a tendency towards a positive correlation between depressive-like behavior and
ASM activity was found (r = 0.54; p = 0.056). As such, rats that showed higher feeding latencies in
the NSF and thereby a more severe depressive-like behavior tended to show higher levels of ASM
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activity in the hypothalamus. A more detailed analysis of ASM activity within distinct hypothalamic
nuclei might reveal whether specific nuclei mediate the effects of ASM on social anxiety. Alternatively,
a high level of ASM activity in other brain regions such as the thalamus and/or ventral striatum might
be necessary to induce social anxiety, given that several studies suggested an important role of the
thalamus [46,47] and the ventral striatum [48,49] in the pathophysiology of social anxiety and that
ASM activity was unaltered in these brain regions in female HAB rats.
Although previous studies investigated the activity of ASM in depressive patients [12] and
in animal models of MDD [29,33], little is known about the contribution of other enzymes of the
sphingolipid metabolism such as NSM, AC and NC in MDD. We showed that the activity of NSM
was also increased in the ventral mesencephalon in female HAB rats, similar to ASM, suggesting that
ASM and NSM might regulate anxiety- and depressive-like behavior together within this brain region.
Similar to ASM, NSM within the dorsal mesencephalon might also regulate anxiety-like behavior
in female HAB rats given that a negative correlation between anxiety levels and NSM activity was
observed, i.e., rats that spent less time on the open arms of the EPM and were thereby more anxious
also showed higher levels of NSM activity in the dorsal mesencephalon.
As ceramide is generated by the activity of ASM and NSM, an increase in ASM and NSM activity
levels is expected to increase ceramide levels and therefore also increase the activity of the enzymes
metabolizing ceramide, i.e., AC and NC. In agreement with this hypothesis, we found an increased
AC activity in the dorsal and ventral striatum, thalamus, hypothalamus and ventral mesencephalon,
whereas the activity of NC was increased in the hypothalamus and dorsal mesencephalon. However,
whether this relatively small but significantly increased activity of ASM and NSM is physiologically
relevant and leads to increased ceramide levels remains to be verified. Mass spectrometry of
brain-specific tissue samples could reveal such alterations in sphingolipid and ceramide species
of different chain length. Moreover, new label-free imaging mass spectrometry techniques could
visualize the distribution and provide quantitative data on various subtypes of lipids in these tissue
sections [32]. In addition, future studies could include mass spectrometry as well as enzyme activity
assays of cerebrospinal fluid samples with detectable levels of both ASM [50] and NSM [51]. Further
enzymes involved in regulating ceramide levels and known to be affected in neuropsychiatric disorders
(e.g., alkaline ceramidase and sphingomyelin synthase [52]) might also play a role and could be altered
in specific brain regions, counterbalancing or increasing the effects of the analyzed sphingomyelinases
and ceramidases.
Taken together, our results add a novel piece of information to the complex regulation of
sphingolipid metabolism, especially of the sphingomyelinases and ceramidases, in MDD and
demonstrate that all investigated enzymes (i.e., ASM, NSM, AC and NC) show predominantly
an increased activity in multiple brain regions associated with anxiety- and depressive-like behavior.
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